Autolus Therapeutics (AUTL) Jefferies Global Healthcare Conference summary

Platform and pipeline overview

• Lead CAR T program under FDA review for acute lymphoblastic leukemia (ALL), aiming for high efficacy and safety.

• Pipeline includes dual-targeting therapies for B-cell malignancies and multiple myeloma, plus a solid tumor program for neuroblastoma.

• Recent clinical work in solid tumors focuses on overcoming hostile microenvironments and evasion mechanisms.

• Integrated commercial manufacturing facility established to support autologous CAR T therapies and upcoming launches.

Clinical data and efficacy insights

• Obe-cel designed for physiological T-cell engagement, balancing high activity with rapid disengagement to avoid overactivation.

• Clinical studies show high activity and safety, with low rates of high-grade cytokine release syndrome and neurotoxicity compared to competitors.

• Long-term follow-up in adults shows 35% ongoing remission at 5 years, with event-free survival stabilizing at 40%.

• Largest CAR T registration study in adult ALL, with 127 patients dosed and strong long-term outcomes without need for subsequent therapy.

• Data suggest stem cell transplant post-CAR T may worsen outcomes due to loss of persisting CAR T cells.

Competitive landscape and differentiation

• Tecartus (Kite Gilead) approved for adult ALL, but studied in a different patient population and shows higher neurological toxicity.

• Obe-cel demonstrates long-term CAR T cell persistence and does not require consolidation with transplant, unlike Tecartus.

• Real-world studies of Tecartus indicate higher neurotoxicity and need for consolidation, contrasting with obe-cel's profile.